Weekly profile.WEEKLY PROFILE AMGEN AMGEN Applied Molecular Genetics (original meaning) INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . Symbol: AMGN Exchange: NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on Close: 58.13 1-WK % Chg: -3.9% Business Overview Amgen Inc. (AMGN), incorporated in 1980, is a global biotechnology company that discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller . It operates in one business segment: human therapeutics. Amgen markets human therapeutic products in the areas of nephrology nephrology Branch of medicine dealing with kidney function and diseases. An understanding of kidney physiology is important not only in treating kidney disease but in knowing the effect of drugs, diet, and hypertension on kidney disease, and vice versa. , supportive cancer care and inflammatory disease. Its principal products include EPOGEN (Epoetin alfa e·po·e·tin al·fa n. A recombinant preparation of human erythropoietin used to treat some forms of anemia. epoetin alfa Epogen, Eprex (CA) (UK), Procrit Pharmacologic class: ), Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and ENBREL (etanercept), which is marketed under a co-promotion agreement with Wyeth in the United States and Canada. Amgen markets its products to healthcare providers, including clinics, hospitals and pharmacies. The Company operates in the United States, Europe, Canada and Australia. On August 13, 2004, Amgen acquired Tularik Inc. (Tularik). Tularik was a company engaged in drug discovery related to cell signaling and the control of gene expression.
WEEKLY PROFILE
Income Statement
2004 2003
Revenue (millions) $10,549.9 $8,356.0
Operating Income (millions) 4,277.0 3,090.5
Net Income (millions) 2,363.3 2,259.5
Diluted EPS (in $) 1.8 $1.69
Summary
Hqtrs: Thousand Oaks
Market Cap: $72.82 billion
Dividend Yield: N/A
P/E Ratio: 24.12
[GRAPHIC OMITTED]
|
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion